| Ytd | 48.02% | |
| 1y | 111.75% |
| Open | 66.26 | Prev Close | 66.74 | Low | 65.65 | High | 66.98 | Mkt Cap | 5.27B |
| Vol | 153.42K | Avg Vol | 1.44M | EPS | -4.70 | P/E | -14.20 | Forward P/E | -13.76 |
| Beta | 0.61 | Short Ratio | 3.56 | Inst. Own | 107.47% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-07 | 50-d Avg | 57.67 | 200-d Avg | 49.14 | 1yr Est | 80.56 |
XENE News
Xenon Pharmaceuticals (XENE) is transitioning into a late-stage, cash-rich neuroscience company with
VANCOUVER, British Columbia and BOSTON, MA, July 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals
Biohaven (BHVN) shares fall as BofA downgrades the stock to Underperform, citing a risky profile ahe
XENE's shares climb 22% in six months as azetukalner delivers strong phase III epilepsy data and adv
VANCOUVER, British Columbia and BOSTON, MA, May 29, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals I
Xenon Pharmaceuticals develops therapies for neurological disorders, with a pipeline targeting epile
Xenon Pharmaceuticals Inc. (XENE) Presents at Bank of America Global Healthcare Conference 2026 Tran
Xenon Pharmaceuticals NASDAQ: XENE said it is preparing to submit a new drug application to the U.S.
Xenon Pharmaceuticals Inc. (XENE) Q1 2026 Earnings Call Transcript
VANCOUVER, British Columbia and BOSTON, MA, May 07, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals I
Polarean highlights 20+ ATS 2026 presentations advancing Xenon MRI as a biomarker platform for trial
VANCOUVER, British Columbia and BOSTON, MA, May 01, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals I
VANCOUVER, British Columbia and BOSTON, MA, April 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc.'s bull case improved after X-TOLE2 showed robust focal seizure reduction
Azetukalner data show significant reductions in seizure frequency across weekly, monthly and multi-y
VANCOUVER, British Columbia and BOSTON, MA, April 15, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals
Five abstracts accepted including Late-breaking Science oral and poster presentations of Phase 3 X-T
Xenon Pharmaceuticals Inc. (NASDAQ: XENE - Get Free Report) was the recipient of unusually large opt
The chief medical officer of Xenon Pharmaceuticals directly sold 1,410 common shares for a transacti
Analysts change outlook on top names: Truist cut KFY price target, Oppenheimer raised AZO target, B.
US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer
US stocks fall as Dow Jones drops over 1% on Monday, while NASDAQ and S&P 500 also decline. Korn
Xenon Pharmaceuticals shares surge after Phase 3 data show strong seizure reduction for azetukalner,
Shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) moved lower during Monday’s session after the co
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earn
Stocks That Hit 52-Week Highs On Thursday